In this issue:
RAPIDO demonstrates a benefit to neoadjuvant chemotherapy for high-risk rectal cancer
Pembrolizumab superior to chemotherapy in dMMR CRC
IDEA compares three versus six months of adjuvant chemotherapy in colon cancer
Duration of adjuvant chemotherapy in high-risk stage 2 CRC
Oxaliplatin should be included in adjuvant chemotherapy for MSI stage 3 colon cancer
Encorafenib + cetuximab for previously treated BRAF–mutant metastatic CRC
Low allele frequency mutation biomarker analysis to predict cetuximab response in CRC
The deleterious impact of COVID-19 on CRC care in England
Biweekly cetuximab plus FOLFOX6 for RAS wild-type metastatic CRC
Sorafenib + irinotecan beneficial for heavily pre-treated RAS-mutated metastatic CRC
Please login below to download this issue (PDF)